RVXCF: Phase 1b/2a Study of RVX-208 Meets Primary Endpoint
Do you know when to trade RVXCF ?
RVXCF | Quote | Chart | News | PowerRating -- By Fain Hughes, fhughes@knobias.com
Resverlogix Corp. (RVXCF) announced that its Phase 1b/2a study testing RVX-208 for 28 days in three different doses has met its primary endpoint of increasing plasma ApoA-I significantly. Quality controls are still ongoing as part of regular good clinical practice, thus the compilation of the full data report should take place within the second half of 2009. As such if there are modifications to this endpoint they will be communicated. This successful data, in combination with the drug showing favorable safety and tolerance characteristics, is expected to see RVX-208 progress into Phase 2 studies in cardiovascular disease patients.
KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com
Knobias.com, LLC
601-978-3399
601-978-3675
info@knobias.com
www.knobias.com/cmtx
For full details on (RVXCF) RVXCF. (RVXCF) has Short Term PowerRatings at TradingMarkets. Details on (RVXCF) Short Term PowerRatings is available at This Link.
- BUYINS.NET: ZANE, GRNO, VTPK, RVXCF, MDHI, PDGRY Have Been Added To Naked Short Lists Today - 03/17/10
- Resverlogix Surges 38% Friday on Cholesterol Drug RVX-208 (PFE,RVXCF) - 03/06/10
- Resverlogix Update - 03/05/10
- Resverlogix Market Update - 03/05/10
- Resverlogix Activates First Site for ASSURE 1 Clinical Trial - 02/25/10
- More News >>


